CPC A61K 47/61 (2017.08) [A61K 9/0048 (2013.01); A61K 9/06 (2013.01); A61K 38/16 (2013.01); A61K 38/177 (2013.01); A61K 38/179 (2013.01); A61K 38/1774 (2013.01); A61K 38/43 (2013.01); A61K 39/3955 (2013.01); A61K 47/32 (2013.01); A61K 47/36 (2013.01); A61K 47/6903 (2017.08); C07K 16/22 (2013.01); A61K 2039/505 (2013.01); C07K 2317/22 (2013.01); C07K 2317/35 (2013.01); C07K 2317/622 (2013.01)] | 16 Claims |
1. A method of treating an ocular disease or disorder in an individual, the method comprising administering to the individual an effective amount of a conjugate comprising:
a) a biologically active polypeptide having a molecular weight of from about 5 kDa to about 2000 kDa, wherein the biologically active polypeptide comprises an antibody specific to vascular endothelial growth factor (VEGF); and
b) a biocompatible polymer having a molecular weight of from about 500 kDa to about 1 MDa,
wherein the polypeptide is covalently linked to the polymer directly or via a linker, and wherein the molar ratio of the biologically active polypeptide to the polymer is at least 25:1,
wherein said administering is by intravitreal administration.
|